The global tumor necrosis factor inhibitors market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic diseases and rising awareness about the benefits of TNF inhibitors. The market is also driven by factors such as increasing number of approvals for TNF inhibitors and growing number of clinical trials for TNF inhibitors. However, high cost associated with these drugs may hamper the growth rate in this market during the forecast period.
The global tumor necrosis factor (TNF) inhibitor market was valued at USD 12,814 million in 2018 and is projected to reach USD 18,907 million by 2030, growing at a CAGR of 5.5% from 2021 to 2030.
Humira dominated the global tumor necrosis factor (TNF) inhibitor market in 2018 with a share of 45%. It was followed by Enbrel with a share of 27%, Remicade with a share of 17%, Simponi with a share of 7%, Orencia with a share 4% and Stelara with 2%.
- Tumor Necrosis Factor Inhibitors market growth is driven by the increasing prevalence of chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease.
- Tumor Necrosis Factor Inhibitors market growth is also driven by the increasing number of cancer cases globally.
- The increase in the number of people suffering from chronic inflammatory diseases and cancer cases has led to an increased demand for Tumor Necrosis Factor Inhibitors drugs which has resulted in a higher market share for these drugs in the global pharmaceutical industry.
- The introduction of new technologies such as gene therapy and immunotherapy have also contributed to the growth of this market segment due to their ability to target specific cells or tissues that are affected by inflammation or cancer respectively without affecting other parts of the body which may be healthy or unaffected by these conditions.
Industry Growth Insights published a new data on “Tumor Necrosis Factor Inhibitors Market”. The research report is titled “Tumor Necrosis Factor Inhibitors Market research by Types (Humira, Enbrel, Remicade, Others), By Applications (Alzheimer's Diseases, Parkinson's Diseases, Ischemic Stroke, Multiple Sclerosis, Others), By Players/Companies EPIRUS Biopharmaceuticals, Bionovis, CASI Pharmaceuticals, Janssen Biotech, Momenta Pharmaceuticals, GlaxoSmithKline, HanAll Biopharma, Intas Pharmaceuticals, LEO Pharma, Dexa Medica, LG Life Sciences, MedImmune”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Necrosis Factor Inhibitors Market Research Report
By Type
Humira, Enbrel, Remicade, Others
By Application
Alzheimer's Diseases, Parkinson's Diseases, Ischemic Stroke, Multiple Sclerosis, Others
By Companies
EPIRUS Biopharmaceuticals, Bionovis, CASI Pharmaceuticals, Janssen Biotech, Momenta Pharmaceuticals, GlaxoSmithKline, HanAll Biopharma, Intas Pharmaceuticals, LEO Pharma, Dexa Medica, LG Life Sciences, MedImmune
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Necrosis Factor Inhibitors Market Report Segments:
The global Tumor Necrosis Factor Inhibitors market is segmented on the basis of:
Types
Humira, Enbrel, Remicade, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alzheimer's Diseases, Parkinson's Diseases, Ischemic Stroke, Multiple Sclerosis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- EPIRUS Biopharmaceuticals
- Bionovis
- CASI Pharmaceuticals
- Janssen Biotech
- Momenta Pharmaceuticals
- GlaxoSmithKline
- HanAll Biopharma
- Intas Pharmaceuticals
- LEO Pharma
- Dexa Medica
- LG Life Sciences
- MedImmune
Highlights of The Tumor Necrosis Factor Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Humira
- Enbrel
- Remicade
- Others
- By Application:
- Alzheimer's Diseases
- Parkinson's Diseases
- Ischemic Stroke
- Multiple Sclerosis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Necrosis Factor Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tumor necrosis factor inhibitors (TNFI) are a type of medication that blocks the action of tumor necrosis factor (TNF), which is a protein that can cause inflammation. TNFI medications are used to treat conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis.
Some of the major players in the tumor necrosis factor inhibitors market are EPIRUS Biopharmaceuticals, Bionovis, CASI Pharmaceuticals, Janssen Biotech, Momenta Pharmaceuticals, GlaxoSmithKline, HanAll Biopharma, Intas Pharmaceuticals, LEO Pharma, Dexa Medica, LG Life Sciences, MedImmune.
The tumor necrosis factor inhibitors market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tumor Necrosis Factor Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tumor Necrosis Factor Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tumor Necrosis Factor Inhibitors Market - Supply Chain
4.5. Global Tumor Necrosis Factor Inhibitors Market Forecast
4.5.1. Tumor Necrosis Factor Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tumor Necrosis Factor Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tumor Necrosis Factor Inhibitors Market Absolute $ Opportunity
5. Global Tumor Necrosis Factor Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Type
5.3.1. Humira
5.3.2. Enbrel
5.3.3. Remicade
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tumor Necrosis Factor Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Application
6.3.1. Alzheimer's Diseases
6.3.2. Parkinson's Diseases
6.3.3. Ischemic Stroke
6.3.4. Multiple Sclerosis
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tumor Necrosis Factor Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tumor Necrosis Factor Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tumor Necrosis Factor Inhibitors Demand Share Forecast, 2019-2026
9. North America Tumor Necrosis Factor Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Application
9.4.1. Alzheimer's Diseases
9.4.2. Parkinson's Diseases
9.4.3. Ischemic Stroke
9.4.4. Multiple Sclerosis
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Type
9.7.1. Humira
9.7.2. Enbrel
9.7.3. Remicade
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tumor Necrosis Factor Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Tumor Necrosis Factor Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Application
10.4.1. Alzheimer's Diseases
10.4.2. Parkinson's Diseases
10.4.3. Ischemic Stroke
10.4.4. Multiple Sclerosis
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Type
10.7.1. Humira
10.7.2. Enbrel
10.7.3. Remicade
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tumor Necrosis Factor Inhibitors Demand Share Forecast, 2019-2026
11. Europe Tumor Necrosis Factor Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Application
11.4.1. Alzheimer's Diseases
11.4.2. Parkinson's Diseases
11.4.3. Ischemic Stroke
11.4.4. Multiple Sclerosis
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Type
11.7.1. Humir
11.7.2. Enbrel
11.7.3. Remicade
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tumor Necrosis Factor Inhibitors Demand Share, 2019-2026
12. Asia Pacific Tumor Necrosis Factor Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Application
12.4.1. Alzheimer's Diseases
12.4.2. Parkinson's Diseases
12.4.3. Ischemic Stroke
12.4.4. Multiple Sclerosis
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Type
12.7.1. Humira
12.7.2. Enbrel
12.7.3. Remicade
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tumor Necrosis Factor Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Tumor Necrosis Factor Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Application
13.4.1. Alzheimer's Diseases
13.4.2. Parkinson's Diseases
13.4.3. Ischemic Stroke
13.4.4. Multiple Sclerosis
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tumor Necrosis Factor Inhibitors Market Size and Volume Forecast by Type
13.7.1. Humira
13.7.2. Enbrel
13.7.3. Remicade
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tumor Necrosis Factor Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tumor Necrosis Factor Inhibitors Market: Market Share Analysis
14.2. Tumor Necrosis Factor Inhibitors Distributors and Customers
14.3. Tumor Necrosis Factor Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. EPIRUS Biopharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bionovis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CASI Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Janssen Biotech
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Momenta Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. HanAll Biopharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Intas Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. LEO Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Dexa Medica
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. LG Life Sciences
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. MedImmune
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
